Your browser is no longer supported. Please, upgrade your browser.
Settings
GALE Galena Biopharma, Inc. daily Stock Chart
GALE [NASD]
Galena Biopharma, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own0.58% Shs Outstand161.73M Perf Week-3.98%
Market Cap273.32M Forward P/E- EPS next Y-0.24 Insider Trans0.00% Shs Float161.03M Perf Month-14.21%
Income-44.60M PEG- EPS next Q-0.09 Inst Own20.20% Short Float11.92% Perf Quarter20.71%
Sales9.90M P/S27.61 EPS this Y63.50% Inst Trans0.19% Short Ratio5.69 Perf Half Y8.33%
Book/sh0.43 P/B3.93 EPS next Y27.30% ROA-51.10% Target Price5.10 Perf Year-46.01%
Cash/sh0.33 P/C5.17 EPS next 5Y- ROE-114.80% 52W Range1.27 - 3.17 Perf YTD11.92%
Dividend- P/FCF- EPS past 5Y24.20% ROI-114.50% 52W High-46.69% Beta1.26
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin84.80% 52W Low33.07% ATR0.13
Employees57 Current Ratio1.70 Sales Q/Q27.30% Oper. Margin- RSI (14)46.16 Volatility5.20% 7.33%
OptionableYes Debt/Eq0.13 EPS Q/Q-300.00% Profit Margin- Rel Volume0.40 Prev Close1.69
ShortableYes LT Debt/Eq0.06 EarningsAug 10 AMC Payout- Avg Volume3.37M Price1.69
Recom2.50 SMA20-9.50% SMA503.94% SMA200-0.47% Volume0 Change0.00%
Mar-09-15Reiterated Needham Buy $7 → $4
Nov-20-14Reiterated MLV & Co Buy $3 → $5
Aug-22-14Reiterated MLV & Co Buy $5 → $3.50
Aug-12-14Reiterated Needham Buy $9 → $7
Feb-03-14Reiterated Noble Financial Buy $4 → $6
Jan-21-14Reiterated Maxim Group Buy $9 → $11
Jan-08-14Reiterated Maxim Group Buy $6 → $9
Nov-26-13Initiated Oppenheimer Outperform $6
Mar-25-13Initiated Needham Buy $3.50
Nov-28-12Initiated Aegis Capital Buy $6
Nov-05-12Initiated Maxim Group Buy $5
Oct-25-12Initiated MLV & Co Buy $6
Jun-04-12Initiated Cantor Fitzgerald Buy $4
Jun-30-15 12:02PM  Small Cap Stocks to Watch in Biotech at Motley Fool
Jun-29-15 09:47PM  Why 78% Is Galena Biopharma's Magic Number at Investopedia -5.68%
Jun-24-15 05:11PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Jun-15-15 07:05AM  Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress GlobeNewswire +5.29%
Jun-10-15 09:14PM  What's Behind Galena's 58% Rise in 2 Weeks? at Investopedia
Jun-08-15 01:38PM  3 Big Stocks on Traders' Radars -- and What to Do With Them at TheStreet
Jun-05-15 09:32AM  Galena Biopharma, Inc. (GALE) Rises: Stock Moves 9.8% Higher - Tale of the Tape +13.20%
May-29-15 03:29PM  2 Small Biotechs This Pro Is Watching
May-28-15 08:29PM  5 Things Galena Biopharma Wants You to Know at Investopedia
04:10PM  Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum GlobeNewswire
12:25PM  Galena Could See Lucrative Partnerships at Barrons.com
08:18AM  Can the Rally in Galena Biopharma (GALE) Shares Continue? - Tale of the Tape
May-27-15 01:42PM  Galena Biopharma rises on cancer therapy study +11.97%
07:05AM  Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-26-15 02:07PM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
May-22-15 07:05AM  Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress GlobeNewswire
May-15-15 01:04PM  GALENA BIOPHARMA, INC. Financials
May-08-15 08:47PM  Galena Biopharma Earnings: NeuVax or Bust at Investopedia
May-07-15 05:00PM  Galena Biopharma Inc Earnings Call scheduled for 5:00 pm ET today
04:20PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
04:15PM  Galena Biopharma Reports First Quarter 2015 Financial Results GlobeNewswire
07:07AM  Q1 2015 Galena Biopharma Inc Earnings Release - After Market Close
May-06-15 08:30AM  Are These in Your Portfolio? 4 Trending Companies (GALE, AEZS, PPCH, THLD) Accesswire
Apr-24-15 04:50PM  Notice of Summons and Complaint Against Defendants Milla Bjorn a/k/a Kamilla Bjorlin and Lidingo LLC in the Shareholder Class Action Against Galena Biopharma, Inc. -- GALE GlobeNewswire
07:00AM  5 Stocks Ready for Breakouts at TheStreet
Apr-23-15 07:05AM  Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015 GlobeNewswire
Apr-22-15 11:46AM  What Adverse Event Reports? FDA Warns Galena For a Lack of Procedures at The Wall Street Journal
Apr-17-15 05:02PM  Notice of Summons and Complaint Against Defendants Milla Bjorn a/k/a Kamilla Bjorlin and Lidingo LLC in the Shareholder Class Action Against Galena Biopharma, Inc. -- GALE GlobeNewswire
Apr-14-15 07:21AM  Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial GlobeNewswire +5.07%
Apr-10-15 01:43PM  Notice of Summons and Complaint Against Defendants Milla Bjorn a/k/a Kamilla Bjorlin and Lidingo LLC in the Shareholder Class Action Against Galena Biopharma, Inc. -- GALE GlobeNewswire
11:15AM  Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million GlobeNewswire
Apr-09-15 05:27PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
08:45AM  Can Galena Biopharma (GALE) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Mar-31-15 09:07PM  4 Ways Galena Biopharma Could Disappoint Investors at Investopedia
07:05AM  Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference GlobeNewswire
Mar-26-15 07:05AM  Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients GlobeNewswire
Mar-18-15 04:35PM  Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire
08:38AM  How Galena (GALE) Stock Stands Out in a Strong Industry - Tale of the Tape
Mar-16-15 01:19PM  Most active Nasdaq-traded stocks
12:33PM  3 Stocks Near 52-Week Lows to Buy Now - Analyst Blog
06:08AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem
Mar-13-15 03:06PM  3 Biotech Stocks on Traders' Radars: Technical Charts at TheStreet -17.92%
09:22AM  Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
Mar-12-15 04:01PM  Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Mar-09-15 04:23PM  Should You Leave Galena To The Day Traders? at Investopedia -5.85%
08:50AM  Galena Biopharma (GALE) Falls: Stock Goes Down 6% - Tale of the Tape
Mar-05-15 06:03PM  Galena Biopharma reports 4Q loss
04:15PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
04:10PM  Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results GlobeNewswire
Mar-03-15 07:05AM  Galena Biopharma to Present at the 27th Annual ROTH Conference GlobeNewswire
Feb-19-15 07:05AM  Galena Biopharma to Report Fourth Quarter and Year End 2014 Financial Results on Thursday, March 5, 2015 GlobeNewswire +5.68%
Feb-09-15 08:50AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:05AM  Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial GlobeNewswire
Feb-05-15 07:05AM  Galena Biopharma Announces Orexo's Filing of a Patent Infringement Lawsuit Against Actavis Concerning Abstral(R) (fentanyl) Sublingual Tablets in the U.S. GlobeNewswire
Jan-28-15 07:05AM  Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-20-15 07:05AM  Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management GlobeNewswire
Jan-15-15 07:05AM  Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annual Investor Conference GlobeNewswire -5.91%
Jan-14-15 04:54PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events EDGAR Online
Jan-08-15 07:05AM  Galena Biopharma Provides 2015 Outlook GlobeNewswire
Dec-15-14 11:49AM  Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ... at TheStreet
Dec-11-14 08:35AM  Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire
Dec-08-14 07:05AM  Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire
Dec-05-14 07:05AM  Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire
Dec-03-14 10:25AM  InMed Pharma's Hiring of Tiberend Highlights Biotech Focus Accesswire
Dec-02-14 07:05AM  Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter GlobeNewswire
Dec-01-14 04:54PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events EDGAR Online
07:05AM  Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire
Nov-25-14 07:05AM  Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference GlobeNewswire
Nov-24-14 09:39AM  Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing at TheStreet -8.70%
Nov-20-14 04:21PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib EDGAR Online
04:20PM  Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC GlobeNewswire
10:05AM  UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided Benzinga
Nov-18-14 07:05AM  Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial GlobeNewswire
Nov-13-14 07:05AM  Galena Biopharma to Present at the Stifel 2014 Healthcare Conference GlobeNewswire
Nov-11-14 07:05AM  Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients GlobeNewswire
Nov-07-14 05:26PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:28PM  Another lackluster session for major equities Yahoo Finance Blogs
07:05AM  Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting GlobeNewswire
Nov-05-14 04:38PM  GALENA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-04-14 07:05AM  Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014 GlobeNewswire
Nov-03-14 05:21PM  Galena Biopharma beats 3Q profit forecasts AP -6.83%
04:33PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online
04:20PM  Galena Biopharma Reports Third Quarter 2014 Results GlobeNewswire
02:00PM  Heat Biologics Takes a New Approach to Immunotherapy Accesswire
07:07AM  Q3 2014 Galena Biopharma Inc Earnings Release - After Market Close CCBN
Oct-27-14 07:05AM  Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014 GlobeNewswire +5.26%
Oct-14-14 07:05AM  Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan GlobeNewswire +5.06%
Oct-09-14 06:51AM  Weakness Seen in Galena Biopharma (GALE) Estimates: Should You Stay Away? Zacks
Oct-08-14 07:05AM  Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination GlobeNewswire
Sep-26-14 05:18PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Sep-25-14 04:15PM  Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update GlobeNewswire
Sep-18-14 04:45PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Sep-09-14 07:05AM  Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial GlobeNewswire
Sep-03-14 07:05AM  Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference GlobeNewswire
Aug-27-14 11:36AM  Why Galena Biopharma (GALE) Stock Is Spiking Today at TheStreet +5.98%
07:59AM  UPDATE: MLV & Co Reiterates On Galena Biopharma On Positive Long-Term Outlook Benzinga
Aug-25-14 08:48AM  Galena Fires CEO Ahn, Offers No Parting Gifts at TheStreet
Aug-22-14 04:47PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stateme EDGAR Online
08:48AM  Biotech Stock Mailbag: Threshold, Galena, CytRx at TheStreet
Aug-21-14 07:16AM  Galena CEO Fired Following Stock-Promotions Scandal at TheStreet -5.17%
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company's lead product candidate comprise NeuVax (nelipepimut-S), which is in Phase III clinical trials for use in the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin that is used for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with Herceptin for use in HER2 gene-amplified breast cancer treatment. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials that is used for the prevention of recurrence in patients with ovarian and endometrial cancers; and GALE-401 (anagrelide controlled release), which has completed Phase I clinical trials that is used for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Portland, Oregon.